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Abstract
Background There are noticeable gaps in knowledge regarding the cost and effectiveness of integrated medical and behav-
ioral services for older adults with HIV. Their lifespan is close to the population’s level but their quality of life has sharply 
declined due to depression and substance use. Mental health disorders are widespread among an aging population with HIV.
Objective The aim of this study was to build a decision analytic model to evaluate medical interventions with and without 
mental health treatment using primary data of 139 older adults with HIV and health outcomes from the literature.
Methods We tracked the progression of depression and cumulative deaths among older adults with HIV using a Markov 
model with 50 annual cycles through three health states. Deterministic and probabilistic sensitivity analyses addressed 
uncertainty in estimating the parameters and around the model’s assumptions.
Results An integrated medical and behavioral care system is cost effective at a willingness to pay of $50,000 per QALY 
compared with medical care only. The incremental cost was $516,452 and the incremental effectiveness was 38.8 quality-
adjusted life-years (QALY), with an incremental cost-effectiveness ratio of $13,316 per QALY.
Conclusions Appropriate and efficacious referrals to integrated medical + behavioral services, either in the same facility 
or connected to their primary care doctor, are instrumental to reverse loses in quality of life and avoid premature death. If 
mental health is left unattended, HIV would progress, causing declines in quality of life and ultimately triggering premature 
death. Reliable data on the cost and effectiveness of different types of HIV integrated services are needed.
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Key Points for Decision Makers 
Mental health disorders reduce quality of life and accel-
erate premature death among older adults with HIV.
A medical + behavioral strategy is cost effective, with 
an incremental cost-effectiveness ratio of $13,316 per 
quality-adjusted life-year.
More evidence-based data on treatment cost and effec-
tiveness is needed to assess the benefits of mental health 
interventions.
1 Introduction
The economics of HIV, aging, and mental health have 
received poor attention in the literature. HIV is a com-
plex medical challenge as well as an economic and public 
health issue. The effect of aging on HIV and whether HIV 
resulted in increased mortality and shortened life expectancy 
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is controversial [1]. The well-being of older adults with 
HIV (OAWH), i.e. individuals 50 years of age and older, 
is adversely affected by low antiretroviral therapy (ART) 
adherence, substance use, depression, social isolation, and 
loneliness. These behavioral disorders cause a decline in 
quality of life (QoL) and premature death among OAWH 
compared with other groups [2]. ART has sharply expanded 
life expectancy for people with HIV [3, 4] but their QoL has 
worsened due to ART toxicity, aging, comorbidities, poly-
pharmacy, and mental health disorders [5–9]. At most, 50% 
of people with HIV under ART suffer from HIV-associated 
neurocognitive disorders (HAND), such as HIV-associated 
dementia, and mild neurocognitive disorders defined as 
lower performance in neurocognitive tests [10–12]. Depres-
sion is a chronic and recurrent disease, seldom identified 
as a factor affecting the outcome of treatment. Episodes of 
depression increase their frequency over time and their dura-
tion is consistent within people with gradual changes over 
time [13]. Untreated behavioral illnesses are associated with 
individuals’ perception of need for care or to social-struc-
tural barriers [14]. Those already linked to HIV treatment 
can benefit from easy access to suitable mental health care, 
ranging from costly clinical interventions for severe depres-
sion to low-cost options through trained health care workers 
or group therapy.
A reasonable question is whether achieving lower depres-
sion levels with analogous increases in QoL for moderately 
or severely depressed OAWH is cost effective. Treating 
people with mild depression reduces the risk of developing 
major depression over time; thus, addressing depression and 
substance use is key in reducing the HIV burden [15–17]. 
Depression is related to low QoL and high medical costs, but 
psychological interventions can reduce depressive episodes 
substantially [18]. There is evidence of the benefits of social 
interaction and engagement on the health and well-being 
among older adults in successful aging [19]; better care is 
positively associated with higher survival rates among HIV-
infected individuals but is suboptimal when patients have 
mental health disorders and are substance users [20]. Behav-
ioral care can be grouped as “pharmacotherapy, psychologi-
cal therapy and the combination of the two” [21]. Some pro-
grams are seemingly low-cost, involving weekly phone calls 
to OAWH from case managers to identify needed resources, 
but others such as cognitive behavioral therapy are provided 
at moderate cost [22–24]. Early interventions are advanta-
geous because HIV progression can be triggered if mental 
health disorders are left unattended [25]. There is narrow 
evidence on the cost effectiveness regarding outcomes for 
patients and the delivery of service when combining HIV 
care and mental health services in different settings [26]. 
HIV medical care integrated with depression and substance 
use treatment could be cost saving and cost effective if it 
identifies specific needs for care [27–29]. Integrated systems 
are cost effective if mental health is provided in HIV clin-
ics [30]; suitably combining group support psychological 
treatment with HIV care is cost effective and cost saving in 
improving the mental health of people with HIV [31].
This paper establishes the cost effectiveness of integrated 
medical and behavioral treatment among OAWH affected by 
mental health disorders.
2  Methods
2.1  Target Population
Estimates show that 70% of Americans infected with HIV 
are aged 50 years or older; people of color, as well as the 
lesbian, gay, bisexual, and transgender (LGBT) community 
face the greater impact [32]. Primary data (n = 139) were 
collected from a non-random sample of 31 HIV-infected 
older White/Caucasian patients and 108 HIV-infected older 
Hispanic patients. Participants were interviewed across HIV 
clinics and community-based groups in New York City. Our 
survey was conducted in the summer of 2018 and included 
questions on socioeconomic, psychosocial, and epidemio-
logical issues. People were screened for eligibility, which 
included being 50 years of age or older, an HIV diagnosis, 
and taking ART at least 12 months previous to the survey. 
Funded by the HIV Intervention Science Training Program 
for Underrepresented New Investigators (HISTP) [33], our 
study was granted Institutional Review Board approval 
for the use of human subjects in research. Informed con-
sent was received from each participant, and participants 
received assurance of confidentiality and privacy. Partici-
pants responding to the Center for Epidemiological Stud-
ies–Depression (CES-D) scale with a score of 16 or higher 
were diagnosed for moderate to severe depression. QoL 
scores were found using the RAND 36-Item Short Form 
Health Survey (SF-36) and transformed into Short Form–6 
Dimension (SF-6D) estimates to obtain utility measures 
using the Sheffield licensing software [34–36], which gener-
ates a set of preference weights from the general population 
to produce QALY approximations using a standard gamble 
health state valuation model (Table 1).
Table 2 shows our utility scores, with a minimum of 
0.459 and maximum of 0.876 (range 0.417), and with a sam-
ple mean of 0.663 (standard deviation [SD] 0.091) and 0.659 
(SD 0.076) for White/Caucasian patients, and 0.665 (SD 
0.095) for Hispanic patients. The utility scores depicted in 
Table 2 under standard gamble health state scores were mul-
tiplied by life expectancy values for the general population at 
79.8 years, and for people with HIV at 71.4 years, generating 
values for effectiveness of treatment. Thus, these indexes 
defined effectiveness as effMildDepress at 48.64 QALYs for 
mild depression, and as effSevereDepress at 43.26 QALYs 
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Table 1  Cost-effectiveness inputs (Markov)
OAWH older adults with HIV, QALY quality-adjusted life-year, SD standard deviation, CI confidence interval, CDC Centers for Disease Control 
and Prevention
Variable Value Description Distribution References
tCycles 50 Number of cycles (years) Estimated
cART1 $24,881 Cost of HIV medical treatment Log-normal distribution (mean $24,881; 
SD $14,219; 95% CI $7621–$61,234)
Gebo et al., 2010 [53]
cMental $45,630 Cost of having behavioral treatment Log-normal distribution (mean 
$45,630; SD $26,075; 95% CI 
$13,976–$112,300)
Weaver et al., 2009 [55]
cMental2 0 Cost of not having behavioral treatment Estimate
pLowRiskDepress 0.588 Probability of low risk of depression Beta distribution (mean 0.588; SD 0.06; 
95% CI 0.468–0.703)
Bhatia and Munjal, 2014 [46]
pHighRiskDepress 0.874 Probability of high risk of depression Beta distribution (mean 0.874; SD 0.05; 
95% CI 0.761–0.954)
Survey, 2018
pDieAIDSDep 0.03 Probability of dying of HIV and depres-
sion
Beta distribution (mean 0.03; SD 0.005; 
95% CI 0.02–0.04)
Estimated
pImprove 0.700 Probability of improving after the 
intervention
Beta distribution (mean 0.700; SD 0.08; 
95% CI 0.53–0.84)
Keller et al., 1992 [53]
AgeStart 50 Starting age of the OAWH Estimated
pDieAIDS 0.014 Probability of dying of HIV CDC, 2019 [52]
eHisp 0.665 Quality of life for Hispanic subjects Survey, 2018
eWhite 0.659 Quality of life for White/Caucasian 
subjects
Survey, 2018
eSample 0.663 Quality of life for the sample Survey, 2018
lifePOP 79.7 Life expectancy for the general popula-
tion
The World Bank, 2020 [38]
lifeHIV 71.4 Life expectancy for people with HIV Samji et al., 2013 [37]
effMildDepress 48.64 QALY for healthy OAWH Estimated
effSevereDepress 43.26 QALY for depressed OAWH Estimated
AgeCurrent 50 (age start) + stage Estimated
TblDeathBack-
ground
Life Table Arias and Xu [54]
Table 2  Depression, utility, and 
quality-of-life scores with eight 
dimensions of health
SD standard deviation, CES-D Center for Epidemiological Studies–Depression, QoL quality of life, SF-36 
Short-Form 36
Sample White subjects Hispanic subjects
Mean (SD) Mean (SD) Mean (SD)
CES-D 15.41 (6.01) 16.23 (4.59) 15.16 (6.37)
QoL score (O ≤ QoL ≤ 1) 0.62 (0.11) 0.64 (0.09) 0.61 (0.11)
Standard gamble health state score 0.663 (0.091) 0.659 (0.076) 0.665 (0.095)
Ordinal health state score 0.679 (0.114) 0.684 (0.109) 0.679 (0.116)
SF-36 Eight Dimensions of Health
Physical Functioning 0.70 (0.25) 0.77 (0.22) 0.68 (0.26)
Role functioning/physical 0.53 (0.44) 0.56 (0.43) 0.52 (0.44)
Role functioning/emotional 0.56 (0.44) 0.57 (0.46) 0.55 (0.44)
Energy/fatigue 0.53 (0.21) 0.49 (0.16) 0.54 (0.23)
Emotional well-being 0.61 (0.23) 0.59 (0.17) 0.62 (0.25)
Social functioning 0.63 (0.29) 0.65 (0.28) 0.62 (0.30)
Pain 0.61 (0.29) 0.73 (0.21) 0.58 (0.30)
General health 0.58 (0.24) 0.64 (0.20) 0.57 (0.25)
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for severe depression. Similar values were computed for His-
panic and White patients [3, 37, 38].
Our subjects included 84.2% males, and 76% lived alone. 
The mean age was 59.1 years (SD 6.6). Only 17% of subjects 
reported some employment status, 67.4% had some college 
education, and 23.8% were undocumented immigrants. Our 
participants experienced high levels of ART adherence, i.e. 
95.2% (standard error [SE] 1.9%) in the sample, 96.6% (SE 
3.4%) in White subjects, and 94.8% (SE 2.2%) in Hispanic 
subjects. The proportion of viral suppression was 95.2% (SE 
1.9%) in the sample, 100% for White/Caucasian subjects, 
and 93.8% (SE 2.4%) for Hispanic subjects; OAWH achieved 
ART adherence, with the corresponding viral load and CD4 
T cells at clinically acceptable levels.
2.2  Decision Model
The Markov model was based on a cohort simulation size 
of 1, which is split into fractions as it spreads through the 
model cycle-by-cycle. We obtained a weighted average of 
all patient pathways based on the assigned probabilities, 
with costs and utilities accumulating along the path via the 
weighted average calculations to obtain the average cost and 
effectiveness per patient. We estimated the cumulative cost 
and effectiveness of behavioral care for OAWH over a finite 
time frame using singular health states.
Figure 1 shows the state transition diagram, which was the 
base upon which to build state rewards using Markov cycle 
trees in TreeAge Pro [39]. We probed the relative health out-
comes of two strategies: medical care only (medical) com-
pared with medical plus behavioral care (medical + behav-
ioral), assuming integrated systems where doctors referred 
patients to suitable mental health services, with follow-up 
over time. Integrated care for OAWH provides ART concur-
rent with mental health treatment to address several forms 
of depression and substance use, conditions that were highly 
prevalent in our sample. This combined intervention can be 
delivered in a single facility, in multiple places, or can be 
facilitated by a case manager or social worker. In each set-
ting, we need to consider cost-effectiveness issues as well as 
potential fragmentation and deficiencies in the coordination 
of services [26].
We simulated the progression of depression and cumu-
lative deaths for 50 years to follow our cohort through-
out their lifetime horizon, using mutually exclusive and 
exhaustive health states, with movements across health 
states determined by transition probabilities. Our model 
included cohort analysis with half-cycle corrections to 
reduce the impact of overestimates [40]. Every cycle 
carries the costs and effectiveness, with a probability of 
developing ‘no to mild depression’, meaning that OAWH 
adhere to ART, stay virally suppressed throughout the 
cycles, and show, at most, mild depression or substance 
use. The risk of feeling ‘moderate to severe depression’ 
represents a person who may adhere to ART, is virally 
suppressed, and experiences at least moderate depression 
being referred and followed-up to behavioral care. The 
criteria for depression was established using the CES-D-
20 survey, in which a participant with a score of 16 points 
or more is considered moderately to severely depressed 
[41, 42]. The probability of ‘dead’ in all health states was 
caused by AIDS or severe mental health conditions and 
mortality caused by factors different from those under 
study [43, 44].
Figure 2  depicts the full decision analytic model. At 
cycle 0, all individuals enjoy relatively good QoL (no to 
mild depression) and remain in good health (StaysMild), 
are diagnosed with depression (depressive), or can die from 
AIDS-related conditions (DieAIDS). OAWH in the moder-
ate to severe depression state experience low QoL but are 
referred to behavioral care, then improve and return to the 
no to mild depression state. If mental health treatment fails, 
the OAWH stays depressed (StayDep) and the likelihood 
of early death increases (DieAIDS + Depress). Background 
death occurs in all health states. The cohort moves between 
health states as time progresses, and then splits among states 
before each cycle is given a probability. The transition sub-
trees are associated with health states occurring within a 
cycle until the terminal node is reached; the cohort then 
returns to a health state for the next cycle via the jump state. 
Fig. 1  State transition diagram of strategies: the circles represent the 
health states and the arrows represent the transition between different 
health states. Individuals can stay in their health states as well as tran-
sit back and forth between health states. Death is the terminal node 
and bears neither cost nor efectiveness rewards
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The strategies of both the medical and medical + behavioral 
cohorts follow the same pattern.
2.3  Cost, Effectiveness, and Probabilities
Table 1 describes the economic evaluation inputs used in the 
Markov model health states [45]. We compared two groups 
of OAWH, one with a low risk of depression of 58.8% 
[46] and those who experienced a high risk of depression 
of 87.4%. Given the probability of improving (pImprove) 
from the intervention, we argue that an initial low level of 
moderate or severe depression among OAWH maximizes 
health and produces the largest number of QALYs for the 
expenditure. Our goal is to compute cost and effectiveness 
derived from mental health care. The rate of dying from 
AIDS-related conditions (pDieAIDS) in the no to mild 
depression group [47–50] was 1.42%, computed from peo-
ple with HIV who died in 2017 divided by the estimated 
prevalence [51]. Because OAWH are at higher risk from 
comorbidities and other factors [52], we reasonably assumed 
the likelihood of dying from AIDS-related and depression-
related conditions (pDieAIDSDep) while being in the mod-
erate to severe depression state was 3%. Keller et al. [53] 
suggested that after consistent and supervised mental health 
treatment, at most 70% of patients recover from depression 
within the year; this value served as the probability of recov-
ering from depression during the cycle (pImprove). Back-
ground mortality was built using the 2017 US Life Tables 
from the Centers for Disease Control and Prevention [54] for 
Fig. 2  Decision analytic model (Markov tree diagram). TreeAge model for decision analysis with two strategies, three health states, and transi-
tion probabilities, representing events within a cycle rather than all scenarios over the entire time horizon
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a period of 50 years (ages 50–100 years) to account for the 
lifetime horizon of our cohort.
The cost-effectiveness analysis (CEA) used a health-
care perspective because the cost of reducing mental 
health disorders is carried by a third-party or by patients 
[55]. There is limited information regarding the treatment 
cost, and data are often retrieved from the current litera-
ture. The average annual cost of medical treatment for 
people with HIV (cART1 in the no to mild depression 
state) was $24,881 per year in 2006 prices inflated to 
2019, based on a large-scale purchaser of services provid-
ing large discounts [56]. These values included the per 
unit cost of clinic visits (inpatient, outpatient, and emer-
gency) multiplied by its frequency, as well as blood tests, 
HIV medications, and opportunistic infection drugs over 
1 year [57]. Weaver et al. [58] used a health sector budget 
view to determine the cost of HIV treatment with inte-
grated care for chronic mental illness and substance abuse 
disorders among HIV-infected individuals (cMental1 for 
the moderate to severe depression state). The cost was 
$45,630 per year in 2009 prices inflated to 2019, com-
prising medical, mental health, and substance abuse visits 
to inpatient, outpatient, and correctional facilities, and 
cost of medications among eight types of services, and 
used Medicare payments for monetary values; this calcu-
lation excluded patient and family costs. The willingness 
to pay (WTP) or “the basis of the Value of a Statistical 
Life and other measures used for calculating the economic 
value of morbidity and mortality improvements” [59] 
was computed using a scalar for the 2018 gross domestic 
product and was set at $50,000 per QALY [60–62]. We 
inflated the cost of HIV and mental health treatment to 
2019 US dollar values to account for inflation, based on 
the Consumer Price Index capturing changes in the prices 
of goods and services purchased by urban households, not 
seasonally adjusted [63]. We applied a 3% discount rate 
for cost and effectiveness occurring in the future.
3  Results
Based on a Markov analysis, the medical + behavioral strat-
egy is cost effective compared with medical-only treatment, 
with a WTP at $50,000 per QALY. Table 3a reports the 
cost-effectiveness rankings for the two strategies, with an 
incremental cost of $518,971, an incremental effective-
ness of 38.8 QALYs, and an incremental cost-effectiveness 
ratio (ICER) of $13,380 per QALY. As originally expected, 
the net monetary benefits (NMBs) are higher for the medi-
cal + behavioral intervention compared with the medical-
only intervention.
3.1  Survivorship and Cumulative Death
The Markov probability analysis graph shown in Fig. 3 
shows that as the cohort moves across the cycles, the sur-
vival curve for no to mild depression lies above the moder-
ate to severe depression curve. The initial depression rate 
was fairly high in our sample, but our model assumes that 
moderate or severe depression was addressed in a timely 
and successful manner by targeted referrals to mental health 
services. The whole cohort starts at stage 0 of the Markov 
simulation but splits in the transition subtrees, where 39.6% 
of the cohort show signs of no to mild depression but 58.5% 
experience moderate to severe depression and 1.9% die 
from causes unrelated to HIV/AIDS or depression in year 
1. We presumed that OAWH with major depression were 
referred to behavioral care, with a 70% chance of improv-
ing within the first year. In year 2, because 70% of those 
patients recovered from depression and returned to the no 
Table 3  Cost-effectiveness 
rankings
Δ Cost represents the difference between the less expensive intervention (medical care only) and the more 
expensive intervention (medical + behavioral care)
Δ Effectiveness represents the difference in effectiveness between our two strategies, ICER represents the 
ratio of incremental cost divided by the incremental effectiveness, NMB represents the monetary value of 
a program given the WTP, Eff effectiveness, ICER incremental cost-effectiveness ratio, NMB net monetary 
benefit, QALYs quality-adjusted life-years, WTP willingness to pay
a Measured in QALYs
b Incremental effectiveness
c Measured in US dollars per QALY
Strategy Cost Δ Cost Effa Δ  Effb,c ICERc NMB
(a) Deterministic
Medical $243,164 1080.8 $53,796,665
Medical + behavioral $759,615 $516,452 1119.6 38.8 $13,316 $55,219,527
(b) Probabilistic
Medical $280,052 1080.8 $53,759,777
Medical + behavioral $886,145 $606,093 1107.2 26.4 $22,946 $54,474,362
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to mild depression state, 56.4% were now in the no to mild 
depression state, 38.9% were in the moderate to severe 
depression state, and the cumulative death rate rises to 4.7%. 
After 25 cycles, only 43.3% of the cohort are still alive, 
being the proportion of individuals with no to mild depres-
sion higher than those in the moderate to severe depression 
cohort; the cumulative death rate is 56.7%. By the end of 
the 50th cycle, < 0.7% of the initial cohort remain alive. The 
medical + behavioral cumulative cost was $762,135 and the 
cumulative effectiveness was 1119.6 QALYs. Because our 
initial depression rate was high, and in the absence of behav-
ioral care, a sizable share of the subjects would have trans-
ited to the depressive state and died due to AIDS-related or 
depression-related conditions. The provision of integrated 
treatment allowed some to recover within 1 year and go back 
to a mild depression state, however some patients relapsed.
3.2  Sensitivity Analysis: Deterministic (DSA) 
and Probabilistic (PSA)
As there are several sources of parameter uncertainty, we ran 
sensitivity analyses with 1000 iterations to fathom how vari-
ations in the input parameters (cost, effectiveness, or prob-
abilities) impacted the results (ICER or NMB). Sensitivity 
analyses accounted for uncertainty in estimating the param-
eter and around the model’s assumptions. We choose a range 
of probability values while keeping the remainder of the 
variables constant. We varied the baseline probability and 
utility estimate values to probe whether the results changed 
given the parameters [64, 65], addressing the unpredictabil-
ity of health states [66, 67]. These values were compared 
with the outputs, considering a WTP of $50,000 per QALY.
3.3  DSA
The one-way sensitivity analysis illustrated in Fig. 4 shows 
the positive relationship between pImprove and NMB 
(monetary value of the intervention given the WTP for a 
unit of benefit) for those who received mental health treat-
ment, measuring the efficacy of the medical + behavioral 
strategy. Likewise, when pImprove increases, the ICER, 
or the cost of an additional unit of perfect health (dollar 
value of QALY), tends to decline. For pDieAIDSDep, both 
the monetary value of the intervention and the per QALY 
cost decline. Figure 5 illustrates that as QALYs increase, 
the NMBs rise and the medical-only strategy is only cost 
effective below 41.45 QALYs, but, above that point, the 
medical + behavioral strategy becomes cost effective, con-
firming that our utility values are within the right bound-
aries. These graphs also indicate that as the number of 
QALYs increase for OAWH who are severely depressed, 
the medical + behavioral strategy has limited benefits and 
Fig. 3  Markov probability 
analysis (medical + behavioral 
strategy). The survival curve 
for no to mild depression lies 
above the moderate to severe 
depression curve. Cumulative 
mortality rises throughout the 
lifetime of the simulation
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stops being cost effective up to 61.8 QALYs; however, 
after this point, the medical-only strategy becomes cost 
effective. The tornado diagram shown in Fig. 6 specifies 
that changes in HIV/AIDS and depression-related mortal-
ity have the greatest effect on outcome, while variations 
in the cost of HIV care have relatively small effects on 
outcome.
3.4  PSA
We conducted a PSA to inspect the effects of several input 
variables on outputs at the same time. A beta distribution 
was used for probabilities, which are bounded between 0 
and 1, while a log-normal distribution was used for the costs 
where the support of the distribution is from zero to infin-
ity. We used a Monte Carlo simulation technique with 1000 
samples and repeated the process several times to ensure that 
the values were stable enough. From the original model, we 
transformed the parameters into distributions to confirm, or 
not, our base case [55, 68–71]. In the original model, we 
defined the medical + behavioral strategy as cost effective, 
however this result provides a moderate but not overwhelm-
ing confidence because the result was based on a predeter-
mined parameter. Our PSA output was similar to the base 
case and confirms that the medical + behavioral strategy is 
cost effective. Table 3b shows the cost-effectiveness rank-
ings, with results confirming those of the original model, 
with an ICER higher in the probabilistic analysis ($22,946) 
compared with the base model ($13,315). Figure 7 intro-
duced the cost-effectiveness acceptability curve (CEAC) 
to establish that at the bottom of the WTP threshold range 
(< $29,000 per QALY), the medical-only strategy has the 
highest probability of being cost effective. The CEAC 
indicates that for a WTP > $29,000 per QALY, the medi-
cal + behavioral strategy has the highest probability of being 
cost effective compared with the alternative. When the WTP 
Fig. 4  One-way sensitivity analysis—pImprove and pDieAIDSDep 
(WTP = $50,000). pImprove is the share of OAWH who recover from 
depression due to mental health care, and pDieAIDSDep is the share 
of OAWH who die due to HIV/AIDS and depression-related condi-
tions, excluding background mortality. WTP willingness to pay, 
OAWH older adults with HIV, ICER incremental cost-effectiveness 
ratio, NMB net monetary benefit
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was $50,000, the medical + behavioral strategy was chosen 
68.8% of the time, but at $100,000, the likelihood of select-
ing the medical + behavioral strategy would be 81.7%. Fig-
ure 8 introduces the incremental cost-effectiveness scatter 
plot displaying the likelihood that our medical + behavioral 
treatment could be chosen, with the share of points within 
the scatter plot falling to the east and south of the WTP line, 
with the slope passing through the origin [72]. We confirmed 
that 68.8% of the points lie to the right of the WTP ray, 
thus make our strategy a superior choice compared with the 
medical-only strategy.
4  Discussion
HIV is multifactorial and requires clinically sound 
approaches concomitant with innovative mental health and 
social and legal services to produce cost-effective outcomes. 
OAWH taking ART are vulnerable to mental health disor-
ders and our sample reported a group of aging people with 
HIV experiencing an unusually high level of mental health 
illness, with a substantial share who did not seek treatment. 
An integrated system is instrumental to significantly reduce 
the effect of the epidemic and achieve better QoL [73]; this 
is important because our sample showed high depression 
Fig. 5  One-way sensitivity analysis—effMildDepress and eff-
SevereDepress (WTP = $50,000). Proxies for treatment effectiveness 
describing the utility of being mildly depressed (effMildDepress) and 
severely depressed (effSevereDepress), both measured in QALYs. 
WTP willingness to pay, QALYs quality-adjusted life-years, NMB net 
monetary benefit, ICER incremental cost-effectiveness ratio
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levels concurrent with substance use and risky sexual 
behaviors, which is consistent with the literature [74–76]. 
Depression is a common and usually misdiagnosed medical 
challenge affecting the lifecycle of OAWH [77–79]; how-
ever, unfortunately, OAWH and older Hispanic patients with 
HIV underutilize mental health services [80, 81]. Moreover, 
social isolation and loneliness are associated with mental 
health disorders and predict poor health and an increased 
likelihood of premature death [82–84]. Psychosocial condi-
tions are both a medical dilemma and an economic conun-
drum affecting OAWH, and, without family and commu-
nity support, behavioral illnesses add $7 billion to Medicare 
costs as a result of longer stays in hospitals [85]. Thus, cost-
effectiveness and cost-saving studies are paramount to better 
understand the resource allocation of clinical interventions.
We proxied psychosocial factors to predict poor health 
and survival rates in our sample of OAWH [86]. We recom-
mended mental health integrated to state-of-the-art medical 
treatment as a cost-effective approach. Although people with 
HIV/AIDS under ART have a low risk of dying as a result 
of the infection [87], there is evidence that death rates are 
higher among people with HIV when compared with the 
general population [48, 88, 89]. In our model, cumulative 
mortality was lower for the medical + behavioral strategy 
compared with the medical-only strategy, suggesting that 
an integrated system that efficaciously links HIV patients 
with assorted mental health services produces the largest 
number of QALYs for the outlay [90]. It is important to 
recognize that psychological disorders represent a syndemic 
of behavioral health issues that include depression, loneli-
ness, trauma derived from having HIV, and substance use 
Fig. 6  Tornado diagram—ICER. Medical + behavioral vs. medical (WTP = $50,000). This graph shows how changes in each input variable 
affect the outcome, and are arranged in decreasing width order. ICER incremental cost-effectiveness ratio, WTP willingness to pay
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[77, 91, 92]. Thus, focusing on these problems in isolation 
will unlikely resolve contributing factors; for instance, treat-
ing depression without acting to reduce social isolation and 
loneliness that may exacerbate, if not be the root cause of, 
this condition [93]. Pharmacological treatment of behavio-
ral health problems is the most cost effective, if combined 
with other therapeutic modalities [94, 95]. Thus, outpatient 
clinics, community-based programs, and individual face-to-
face psychotherapy combined with other remedies are at the 
high-end regarding effectiveness and cost. These costs can 
be reduced with high efficacy through the use of telemedi-
cine or group therapy [96], with the caveat that technology 
can also be a source of health disparities. Small and closed 
groups based on positive psychology principles with ele-
ments of psychoeducation and therapeutic effects of group 
participation have been proven to be effective [97]. An adap-
tation of the MacArthur Project, with respect to interven-
tion for OAWH, is a low-cost and scalable social support 
program that, in combination with treatment as usual, halved 
depressive symptom scores over a 6-month period [98]. 
These interventions reduce social isolation and promote 
social interaction through group therapy or weekly phone 
calls from a care manager. The use of mobile phone tech-
nologies offers additional low-cost and high efficacy options 
for reducing mental health problems in OAWH in resource-
poor areas in Latin America and sub-Saharan Africa [99, 
Fig. 7  CEAC (WTP = $50,000), which was based on 1000 iterations or samples to summarize uncertainty of the estimates. CEAC cost-effective-
ness acceptability curve, WTP willingness to pay
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100], and was particularly effective in reducing social isola-
tion among people with HIV in rural areas. In addition, the 
trauma-informed peer support for people living with HIV 
can be cost effective [101]. Thus, mental health interventions 
that are able to address the multifaceted causes of psycho-
logical distress among OAWH can be highly effective, but 
are not always high-cost programs.
The lack of evidence-based cost studies for the gradi-
ent of HIV and mental health interventions is a limitation 
of our study. Furthermore, non-probability samples do not 
contain all members of a population and carry lower levels 
of generalization. Time is a crucial parameter of Markov 
models that facilitates the analysis of chronic diseases, thus 
future states depend only on the current states and not on 
Fig. 8  Scatter plot of incremental cost-effectiveness: medi-
cal + behavioral versus medical. This scatter plot identifies the prob-
ability that the new treatment is cost effective, where the vertical axis 
represents the incremental cost, the horizontal axis is the incremental 
effectiveness, and the ellipses denote 90% and 95% confidence inter-
vals. More than 68.8% of the points lie to the right of the WTP ray, 
thus make our strategy a superior choice compared with ‘medical’ 
only. WTP willingness to pay
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the path followed in the past [102]. This could be restrictive 
for specific diseases and models with many states. Cohort 
simulations assume an homogeneous population with con-
stant risk throughout the time horizon. CEAs use refined 
statistical and standardized procedures and serves as a guide 
for resource allocation [103]. Markov models are simple and 
easy to understand for a broader audience but can be con-
tentious because they assign implicit and explicit monetary 
values on human life, therefore decision makers can use this 
knowledge to control expenses. CEAs have been extensively 
used in economic evaluations but seldom discuss issues of 
fairness and equity. Our findings cannot serve as a substitute 
for value judgments.
5  Conclusions
We determined that an integrated system (medical + behav-
ioral) is cost effective to improve QoL among OAWH. We 
produced a computer-generated progression of mental health 
and death to synthesize information using a Markov model 
based on simple mathematical constructions [104]. As 
simulated in our model, assuming effective identification 
of mental health disorders and proper referral to care is key 
to producing better health outcomes. Our findings inform 
how resource allocation can improve health outcomes based 
on our sample results. Policy makers need to prioritize the 
share of people virally suppressed with the addition of men-
tal health care in the midst of the ‘graying’ of the epidemic.
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